24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii]
methylphenidate hydrochloride
RxCUI: 2668499
What the CMS Formulary Data Shows for 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii]
Per the CMS 2026 Part D formulary file, 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] (RxNorm concept RXCUI 2668499, generic name methylphenidate hydrochloride) appears on 4 distinct formulary files spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 3, with a cross-plan average of Tier 2.
Real-world access to 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 100% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] today.
Coverage Details
- Formularies covering
- 4
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 3
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 100% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | No | $0 | MA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T3 | No | $0 | MA |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T3 | No | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T3 | No | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T3 | No | $147.20 | MA |
Frequently Asked Questions
Is 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] covered by Medicare Part D?
Yes, 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] on Medicare Part D plans?
24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] averages Tier 2 across Part D plans, ranging from Tier 1 to Tier 3.
Does 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii] require prior authorization?
0% of Part D formularies require prior authorization for 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet [Relexxii]. Step therapy: 0%. Quantity limits: 100%.
Read our methodology - how this data is sourced, computed, and verified.